Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Moriggl

Showing results (1-10 of 196) with videos related to

Pageof 20
Sort By:
Journal of Leukocyte Biology|June 4, 2014
Recovery from chemotherapy depends on STAT1 for replenishment of B lymphopoiesisBirgit Strobl, Richard Moriggl
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2008
A detailed protocol for bacterial artificial chromosome recombineering to study essential genes in stem cellsAndriy Tsyrulnyk, Richard Moriggl
Hepatology (Baltimore, Md.)|June 11, 2013
Reply: To PMID 21725989Kristina M Mueller, Richard Moriggl
JAK-STAT|September 24, 2013
Acetylation and sumoylation control STAT5 activation antagonisticallyOliver H Krämer, Richard Moriggl
Haematologica|October 3, 2019
The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axisAnna Orlova, Heidi A Neubauer, Richard Moriggl
Cytokine|December 20, 2018
Editorial: Cytokines in liver diseasesSubburaj Ilangumaran, Richard Moriggl, Dhan V Kalvakolanu
Bioscience Trends|February 4, 2017
Steering of carcinoma progression by the YIN/YANG interaction of STAT1/STAT3Karlheinz Friedrich, Helmut Dolznig, Xiaonan Han, et al.
Cytokine|January 22, 2021
A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammationMarta Surbek, William Tse, Richard Moriggl, et al.
Oncotarget|October 22, 2014
Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemiaAngelika Berger, Veronika Sexl, Peter Valent, et al.
Molecular & Cellular Oncology|June 8, 2018
A haunted beast: Targeting STAT5B<sub>N642H</sub> in T-Cell NeoplasiaHa Thi Thanh Pham, Markus Hengstschläger, Richard Moriggl
Pageof 20

Showing results (1-10 of 196) with videos related to

Sort By:
Pageof 20
Journal of Leukocyte Biology|June 4, 2014
Recovery from chemotherapy depends on STAT1 for replenishment of B lymphopoiesisBirgit Strobl, Richard Moriggl
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2008
A detailed protocol for bacterial artificial chromosome recombineering to study essential genes in stem cellsAndriy Tsyrulnyk, Richard Moriggl
Hepatology (Baltimore, Md.)|June 11, 2013
Reply: To PMID 21725989Kristina M Mueller, Richard Moriggl
JAK-STAT|September 24, 2013
Acetylation and sumoylation control STAT5 activation antagonisticallyOliver H Krämer, Richard Moriggl
Haematologica|October 3, 2019
The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axisAnna Orlova, Heidi A Neubauer, Richard Moriggl
Cytokine|December 20, 2018
Editorial: Cytokines in liver diseasesSubburaj Ilangumaran, Richard Moriggl, Dhan V Kalvakolanu
Bioscience Trends|February 4, 2017
Steering of carcinoma progression by the YIN/YANG interaction of STAT1/STAT3Karlheinz Friedrich, Helmut Dolznig, Xiaonan Han, et al.
Cytokine|January 22, 2021
A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammationMarta Surbek, William Tse, Richard Moriggl, et al.
Oncotarget|October 22, 2014
Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemiaAngelika Berger, Veronika Sexl, Peter Valent, et al.
Molecular & Cellular Oncology|June 8, 2018
A haunted beast: Targeting STAT5B<sub>N642H</sub> in T-Cell NeoplasiaHa Thi Thanh Pham, Markus Hengstschläger, Richard Moriggl
Pageof 20